Tuesday, March 28, 2017

Cellect Biotechnology (APOP) Soared To A New High After Stem Cell Transplant

Cellect Biotechnology Ltd. (APOP) announced Monday morning that the first stem cell transplant procedure has been successfully performed using its ApoGraft technology in its Phase I/II clinical trial in a blood cancer patient.

from RTT - Before the Bell http://ift.tt/2nrmco2
via IFTTT

No comments:

Post a Comment